Ornithine Phenylacetate

鸟氨酸苯乙酸盐

Report date: 2025/07/14 20:01:16

Base Information

Drug NameOrnithine Phenylacetate
Drug Alias NameL-Ornithine phenylacetateSodium phenylacetate/ornithine hydrochlorideOrnithine hydrochloride/sodium phenylacetateL-OPOCR-002 +[9] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionNitric oxide synthase, inducible modulatorsNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complexNitric oxide synthase, inducible
Therapy Area/IndicationsAcute liver injuryLiver CirrhosisLiver Failure, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[18] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYaqrit LtdMallinckrodtOcera Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAcute liver injuryLiver CirrhosisLiver Failure, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG